Alexion Pharmaceuticals, Inc. ALXN
Alexion's stand-alone strategy has failed — serial M&A missteps and a deep valuation discount mean the Board must pursue a sale now to unlock 40-50% upside for shareholders.
Thesis
Elliott, a long-term Alexion holder since 2017, argues that despite strong operational execution under CEO Ludwig Hantson the market has rendered a decisive verdict against the 'go-it-alone' strategy: ALXN is the worst TSR performer in large-cap biopharma over Chairman Brennan's tenure, trailing the proxy peer average by 45-58% across one-, two- and three-year windows. A cascade of six missteps — capped by the Achillion and Portola acquisitions that destroyed $2.9bn of market value (137-166% of transaction EV) — has shattered investor trust. ALXN now trades at 6.1x 2021 EV/EBITDA, a ~50% discount to pharma peers, implying a negative five-year revenue CAGR versus management's double-digit ambition. With operational fixes, M&A, merger-of-equals and buybacks all judged inadequate, Elliott urges the Board to immediately explore a sale to close the ~40-50% gap to fair value.
SCQA
Alexion is a leading rare-disease biopharma with a world-class complement franchise (Soliris/Ultomiris), 55%+ EBITDA margins, $2bn+ annual FCF and IP protection through 2035 — fundamentally strong in a fundamentally strong industry.
Despite operational improvements since 2017, the market has priced in terminal decline: ALXN is the worst TSR performer in large-cap biopharma, and the Achillion and Portola deals destroyed $2.9bn, erasing 137-166% of transaction EV and shattering Board credibility.
The Board must immediately abandon the stand-alone strategy and explore a sale of the Company; operational tweaks, further M&A, a merger of equals and capital returns have all been evaluated and judged insufficient to restore confidence.
Sell-side analysts see ~40% median upside to fair value (vs. 6% for biotech peers); a strategic acquirer applying a large-cap pharma WACC of under 11% would crystallize a ~40-50% discount-to-fair-value gap plus synergies.
The three reasons
- 1
ALXN is the worst TSR performer in large-cap biopharma under Brennan's chairmanship
- 2
Achillion and Portola deals destroyed $2.9bn — 137-166% of transaction EV
- 3
ALXN trades at ~50% discount to pharma peers despite 8% CAGR and 55%+ EBITDA margins
Primary demands
- Immediately explore a sale of the Company to a strategic acquirer
- Acknowledge the limitations of the stand-alone strategy and act with urgency on strategic alternatives
- Refresh the Board with fresh perspectives following years of value destruction
- Halt further large-scale M&A, which would be viewed as an act of desperation
KPIs cited
Pattern membership
Where this document fits across the library's 12 rhetorical / structural patterns.
Precedents cited
- Synageva acquisition (disastrous prior Alexion M&A)
- Copaxone / Teva 40mg generic switch (complement franchise defensibility analogue)
Notable slides (5)
Notes
Public letter from Elliott Advisors (UK) to Alexion Chairman David Brennan, cc'd to Board and CEO Hantson. Elliott explicitly states it first made the sale recommendation privately in December 2019; the Portola announcement (5-May-2020, -7.3% one-day) prompted going public. No stake percentage disclosed in the letter itself. Signed by the firm (Elliott Advisors (UK) Limited), not by a named individual. Campaign outcome: Alexion was ultimately acquired by AstraZeneca in a deal announced December 2020 — Elliott won. Rhetoric is constructive-adversarial: praises Hantson's operational execution while demolishing Board credibility. Heavy use of sell-side analyst quotes (JPM, MS, Stifel, Jefferies, BAML, Evercore, RBC, Raymond James) to triangulate thesis. Standout visual: page 7 regression of EV/EBITDA vs. 5yr revenue CAGR with annotated circles separating pharma vs. biotech trading ranges.